Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

In recent years, many patients like Mitchell have faced soaring insulin costs. These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and ...

Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus Monday, one of the country’s top antitrust watchdogs said her agency is ...

The Federal Trade Commission (FTC) has sued the top three ... system" that it claims artificially inflated the prices of insulin products. The lawsuit – which has been anticipated since the ...

High insulin prices have been a hot topic in ... “The Biden administration, Congress, the Federal Trade Commission, and others need to do everything in their power to address the anti ...

Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts. Georgia Gov. Brian Kemp, though, vetoed a related bill that ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

CVS Health is one of three pharmacy benefit managers targeted in a lawsuit from the Federal Trade Commission, which has accused the companies of driving up the price of insulin. The three firms ...

Now, the Federal Trade Commission (FTC) is suing the largest PBMs for allegedly increasing the cost of insulin for patients with diabetes. These middlemen manage the drug benefits for virtually ...

The Inflation Reduction Act championed by President Joe Biden and congressional Democrats included provisions limiting the cost of insulin ... also urged the Federal Trade Commission and the ...

Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...

In August 2022, Ms. Harris cast the tiebreaking vote in the Senate to pass the Inflation Reduction Act, which granted CMS the power to negotiate the price of select prescriptions, targeting ...